Clinical trial NCT02799524: Comparison of Mood Disorders Screening Scales in Geriatric Oncology
Official title: Comparison of Mood Disorders Screening Scales in Geriatric Oncology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mood Disorders
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
Collaborators: name: Centre Francois Baclesse
First posted: 2016-06-15
Enrollment: 93
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and women 70 years and older with newly diagnosed or relapsed cancer or haematological malignancies (not older than one month)

Brief summary: The objective of this study is to evaluate the scales commonly used in geriatrics and oncology distress thermometer ( analogue scale rated from 0 to 1 for the emotional distress ) , the GDS15 (15 issues closed binary response seeking signs of depression ) the HADS (14 questions assessing the intensity of anxiety signs and signs of depression listed 0-3 ).

The prospective observational study will be conducted in parallel on two sites ( University Hospital Centre and François Baclesse ) after informed patient information.

It will be offered to patients 70 years and over with a new diagnosis or relapse of cancer or haematological malignancies in the hospital to meet the mood disorder screening questionnaires .

Detailed description: There are various tools validated and recommended by the SiO and SFPO for screening mood disorders in geriatric oncology . The choice among them depends on the usual practices of the various teams , only some scales assessing depressive signs and other signs of anxiety too. None were assessed in a population aged diagnosis of cancer or hematologic malignancy in pre- therapeutic situation.

The objective of this study is to evaluate the scales commonly used in geriatrics and oncology distress thermometer ( analogue scale rated from 0 to 1 for the emotional distress ) , the GDS15 (15 issues closed binary response seeking signs of depression ) the HADS (14 questions assessing the intensity of anxiety signs and signs of depression listed 0-3 ) The prospective observational study will be conducted in parallel on two sites ( University Hospital Centre and François Baclesse ) after informed patient information.

It will be offered to patients 70 years and over with a new diagnosis or relapse of cancer or haematological malignancies in the hospital to meet the mood disorder screening questionnaires .

If one test is abnormal , a clinical psychological care will be offered . When returning home : telephone contact will be made the same day with the doctor , asking him to please make thymic revaluation within 2 weeks ( informed patient). It will be sent to the doctor by post a rubric of Major Depressive Episode criteria of the DSM V to return . If the patient remains hospitalized , the doctor taking care of patient will be contacted to obtain the same information .

In addition, the investigators will study the impact on the management (change or introduction of an antidepressant and / or anxiolytic use of psychotherapy or psychological counseling ... ) to 5 weeks

Eligibility criteria: Inclusion Criteria:

* Patient 70 years and older with diagnosis of cancer or haematological malignancies ,
* New diagnosis or relapse announced
* Supported in the 2 c among : in consultation , or hospital geriatric or oncology / hematology specialty
* Affiliated Health Insurance

Exclusion Criteria:

* Cognitive problems preventing self

Primary outcomes:
measure: Concordance degrees Assessment (HADS and GDS )
timeFrame: 3 weeks
Secondary outcomes:
measure: Correlation between the presence of signs of depression screening by HADS -D ( ≥11 / 21) and GDS ( > 5/15)
timeFrame: 3 weeks
measure: correlation between anxious signs of HADS -A ( ≥11 / 21) and the distress thermometer ( ≥4 / 10) and factors outcome 2
timeFrame: 3 weeks
measure: Comparison of the distress thermometer score between screening and revaluation to 3 weeks
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Caen
country: France
facility: Caen UH
Study officials:
References: